Moss, 23 August 2017
Gentian Diagnostics AS announces its results for the second quarter
and first half year. The highlights of the quarter include:
- IVD CE marking and commercial launch for GCAL: calprotectin
in blood samples
- 81 % growth in revenue q/q and 12 % y/y
- Two more patent applications were filed
Please find the report for the second quarter and first half year
enclosed. The report will also be made available on www.gentian.no.
For further information, please contact:
Bård Sundrehagen
CEO, Gentian Diagnostics
E-mail: Bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117